Trial Profile
An Open-label Fixed Sequence Trial to Investigate the Potential Drug-drug Interaction of Intravenous Volasertib Co-administered With a P-gp and CYP3A4 Inhibitor (Itraconazole p.o.) in Patients With Various Solid Tumours
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Sep 2023
Price :
$35
*
At a glance
- Drugs Volasertib (Primary) ; Itraconazole
- Indications Advanced breast cancer; Colon cancer; Head and neck cancer; Non-small cell lung cancer; Rectal cancer; Soft tissue sarcoma; Solid tumours
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 05 May 2021 Status changed from active, no longer recruiting to completed.
- 20 Apr 2021 Planned End Date changed from 12 Apr 2021 to 11 May 2021.
- 22 Feb 2021 Planned End Date changed from 12 Mar 2021 to 12 Apr 2021.